Collegium Pharmaceutical, Inc. COLL Net interest and investment income (loss)
Net interest and investment income (loss) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s net interest and investment income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s net interest and investment income (loss)?
- Collegium Pharmaceutical, Inc. (COLL) reported net interest and investment income (loss) of $3.71M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s net interest and investment income (loss) changed year-over-year?
- Collegium Pharmaceutical, Inc.'s net interest and investment income (loss) increased by 66.6% year-over-year, from $2.23M to $3.71M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s net interest and investment income (loss)?
- Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s net interest and investment income (loss) has grown at a 453.8% compound annual growth rate (CAGR), from $12K to $11.29M.